Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-IntermediateStaphylococcus aureusIsolates-Reference-Cited by-同舟云学术

Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-IntermediateStaphylococcus aureusIsolates

Published:2010-11-15 Issue:1 Volume:55 Page:405-410
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob. Agents Chemother.

Author:

van Hal Sebastiaan J.,Paterson David L.

Abstract

ABSTRACTThe prevalence of heteroresistant vancomycin-intermediateStaphylococcus aureus(hVISA) is 1.3% in published studies. Clinical associations include high-inoculum infections and glycopeptide failure, with hVISA infections associated with a 2.37-times-greater failure rate (95% confidence interval [CI], 1.53 to 3.67) compared to vancomycin-sensitiveStaphylococcus aureus(VSSA) infections. Despite this, 30-day mortality rates were similar to those for VSSA infections (odds ratio [OR], 1.18; 95% CI, 0.81 to 1.74). The optimal therapy for hVISA requires further study.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference61 articles.

1. Adam, H. J., L. Louie, C. Watt, D. Gravel, E. Bryce, M. Loeb, A. Matlow, A. McGeer, M. R. Mulvey, and A. E. Simor. 2010. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. Antimicrob. Agents Chemother. 54:945-949.

2. Ariza, J., M. Pujol, J. Cabo, C. Pena, N. Fernandez, J. Linares, J. Ayats, and F. Gudiol. 1999. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-1588.

3. Aucken, H. M., M. Warner, M. Ganner, A. P. Johnson, J. F. Richardson, B. D. Cookson, and D. M. Livermore. 2000. Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus. J. Antimicrob. Chemother. 46:639-640.

4. Bae, I. G., J. J. Federspiel, J. M. Miro, C. W. Woods, L. Park, M. J. Rybak, T. H. Rude, S. Bradley, S. Bukovski, C. G. de la Maria, S. S. Kanj, T. M. Korman, F. Marco, D. R. Murdoch, P. Plesiat, M. Rodriguez-Creixems, P. Reinbott, L. Steed, P. Tattevin, M. F. Tripodi, K. L. Newton, G. R. Corey, and V. G. Fowler, Jr. 2009. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J. Infect. Dis. 200:1355-1366.

5. Bert, F., J. Clarissou, F. Durand, D. Delefosse, C. Chauvet, P. Lefebvre, N. Lambert, and C. Branger. 2003. Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. J. Clin. Microbiol. 41:5147-5152.

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What is the clinical significance of ‘heteroresistance’ in nonfermenting Gram-negative strains?;Current Opinion in Infectious Diseases;2023-09-20

2. Overview of heteroresistance, persistence and optimized strategies to control them;REV RES MED MICROBIO;2023

3. Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside;Clinical Microbiology and Infection;2023-03

4. Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: Host, Pathogen, and Treatment;Antibiotics;2023-02-24

5. Heterogeneous Vancomycin Intermediate Staphylococcus aureus Infections in Diabetic and Non-Diabetic Patients – A Hospital-Based Comparative Study;Infection and Drug Resistance;2023-01